OmniAb (OABI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 17, 2025, at 8:00 a.m. Pacific Time in Emeryville, CA.
Proxy materials are available online, with options for electronic or paper delivery.
Shareholders are encouraged to review all proxy materials before voting.
Voting matters and shareholder proposals
Election of two directors: Carolyn R. Bertozzi, Ph.D., and John Higgins.
Ratification of Ernst & Young LLP as the independent registered accounting firm.
Board recommends voting FOR all nominees and FOR the auditor ratification proposal.
Board of directors and corporate governance
Board of Directors has nominated two individuals for election at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from OmniAb
- Over 400 active programs and new technology launches drive growth and future cash flow.OABI
Corporate presentation24 Mar 2026 - 107 partners, 407 programs, new platforms, and 2026 revenue growth expected.OABIQ4 20254 Mar 2026
- Q2 revenue up 10% to $7.6M, net loss narrowed, and partnerships and cash remain strong.OABIQ2 20242 Feb 2026
- Expanding partnerships and innovative antibody platforms drive growth and long-term royalties.OABIJefferies Global Healthcare Conference31 Jan 2026
- Q3 revenue fell to $4.2M, but partner and program growth and $59.4M cash support future progress.OABIQ3 202414 Jan 2026
- Double-digit partner and program growth, Q4 revenue up, 2025 revenue seen at $20–$25M.OABIQ4 202424 Dec 2025
- Resale registration covers 21.25M shares from a $30M private placement; no proceeds to company.OABIRegistration Filing16 Dec 2025
- OmniUltra enables novel antibody and peptide discovery, targeting a trillion-dollar market.OABIInvestor Update16 Dec 2025
- Annual meeting to elect directors and ratify auditor, with focus on governance and ESG.OABIProxy Filing2 Dec 2025